home > ebr > autumn 2018 > candidate selection


Dear guest!

article: Candidate Selection
format: Adobe Acrobat PDF file
cost: £


News and Press Releases

Ubiquigent Appoints Dr Sheelagh Frame, CSO, to Its Board of Directors

Dundee, UK, 24 October 2022: Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitylase (DUB) modulators as powerful new therapeutics, today announced the appointment of Dr Sheelagh Frame, Chief Scientific Officer (CSO), to the Company’s Board of Directors. The appointment comes at a key stage in the Company’s development with the growing importance of the DUBs in drug discovery and will help drive the progress of Ubiquigent’s internal portfolio of novel DUB modulators, associated drug discovery programmes and commercial services.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement